tyrosine has been researched along with cardiovascular agents in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackman, M; Humphries, K; Jackevicius, C; Kertland, H; Shalansky, SJ; Tsuyuki, R; Virk, R | 1 |
| ANDREOTTI, L; BIANUCCI, GF; SIBILLA, A | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Brauns, SC; Dyason, K; Jamie, H; Kilian, G; Milne, PJ | 1 |
| Akdemir, R; Cagirci, G; Karakurt, O; Kilic, H | 1 |
| Anselmi, M; Biondi-Zoccai, G; Boccuzzi, G; Bolognese, L; Campo, G; de Cesare, N; Díaz Fernández, JF; Ferrari, R; Malagutti, P; Moreno, R; Parrinello, G; Penzo, C; Ribichini, F; Rodriguez, AE; Russo, F; Valgimigli, M | 1 |
| Anselmi, M; Bolognese, L; Bressers, M; Bristot, L; Campo, G; Colangelo, S; De Cesare, N; Gambetti, S; Garcia-Garcia, HM; Garg, S; Monti, M; Moreno, R; Parrinello, G; Rodriguez, AE; Sarno, G; Serruys, PW; Valgimigli, M | 1 |
1 review(s) available for tyrosine and cardiovascular agents
| Article | Year |
|---|---|
Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S
Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Drug-Eluting Stents; Evidence-Based Medicine; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
6 other study(ies) available for tyrosine and cardiovascular agents
| Article | Year |
|---|---|
Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
Topics: Abciximab; Antibodies, Monoclonal; Canada; Cardiovascular Agents; Clopidogrel; Dalteparin; Data Collection; Drug Utilization; Enoxaparin; Eptifibatide; Formularies, Hospital as Topic; Health Services Accessibility; Hematologic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Pharmacy and Therapeutics Committee; Ticlopidine; Tirofiban; Tyrosine | 2003 |
[PLASMINOGEN LEVEL IN PREGNANCY AND ITS POSSIBLE RELATIONS WITH THE BLOOD LEVEL OF FREE PLASMATIC CORTICOSTEROIDS].
Topics: Adrenal Cortex Hormones; Blood; Cardiovascular Agents; Dermatologic Agents; Female; Fibrinolysin; Glucocorticoids; Humans; Plasminogen; Pregnancy; Tyrosine | 1964 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Biological activity of selected tyrosine-containing 2,5-diketopiperazines.
Topics: Algorithms; Animals; Antineoplastic Agents; Binding, Competitive; Brain Chemistry; Calcium Channels; Cardiovascular Agents; Cell Line, Tumor; Coronary Circulation; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Heart; Heart Conduction System; Heart Rate; Humans; In Vitro Techniques; Male; Membrane Potentials; Patch-Clamp Techniques; Piperazines; Potassium Channels; Rats; Rats, Long-Evans; Receptors, Opioid, mu; Tyrosine | 2005 |
Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment.
Topics: Adult; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Male; Sirolimus; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolim
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Sirolimus; Stents; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |